Recordings of the webinar will soon be available on EASL Campus. The link will appear here.
Ansgar Lohse: Optimizing standard therapy for Autoimmune Hepatitis
Eleonora De Martin: Acute severe Autoimmune Hepatitis
Christina Weiler-Normann: 3rd line therapy for Autoimmune Hepatitis
Prof. Dr. Ansgar W. Lohse is Director of the I. Department of Medicine at the University Medical Centre Hamburg-Eppendorf (UKE), Germany, since 2005. He is also the coordinator of the European Reference Network on hepatological Diseases (ERN RARE-LIVER) since 2018. He studied medicine and philosophy in Göttingen, London and Boston from 1978 – 1984 and received his Doctorate in 1987 at the University of Marburg. After a two-year research stay at the Weizmann Institute of Science in Israel he worked both clinically and in research at the Johannes Gutenberg-University Mainz. He is specialist in gastroenterology and infectious diseases, with special interest in basic and clinical immunology.
Eleonora De Martin, MD, Phd, is a transplant hepatologist at Centre Hépato-Biliaire, Paul Brousse Hospital in France. She is the Vice-Chair of ILTS Vanguard Committee and topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group. Her fields of interest include various aspect of liver transplantation, autoimmune hepatitis in particular severe acute and fulminant forms and hepatic toxicity of immunotherapy for metastatic cancer.
Dr. Christina Weiler-Normann is working as a consultant at I. Department of Medicine and Martin Zeitz Centre for Rare Diseases at University Medical Centre Hamburg-Eppendorf, Germany. She studied Human Medicine from 1995 – 2002, finished her Dissertation in Human Medicine (Dr. med.) under the supervision of Prof. Dr. Lohse in 2002 and has worked as junior doctor from 2002 – 2003 at the University of Mainz, Germany. From 2004 – 2006 she worked as a Postdoctoral Fellow in the National Institutes of Health, Bethesda, USA. She is a Specialist in Gastroenterology and Hepatology with a special interest in autoimmune liver diseases.